2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Polycystic Ovary Syndrome
7
Obesity
5
Weight Loss
2
Infertility, Female
2
Infertility
2
Sexual Infantilism
1
Prediabetic State
1
Pancreatic Neoplasms
1
Obesity, Abdominal
1
Metabolic Syndrome
1
Insulin Resistance
1
Inflammation
1
Glucose Intolerance
1
Dyslipidemias
1
Diabetes Mellitus, Type 2
1
Craniopharyngioma
1
Combined Pituitary Hormone Deficiency
1
Cardiovascular Diseases
1
Interventions
Exercise
4
Cholecalciferol
4
Aspirin
4
Nutrition Assessment
3
Gonadotropin-Releasing Hormone
3
Blood Pressure
3
Atorvastatin
3
palbociclib
2
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2
acalabrutinib
2
Vitamin E
2
Vitamin D
2
Social Determinants of Health
2
Rosuvastatin Calcium
2
Methods
2
Metformin
2
Geritol
2
Fish Oils
2
Fatty Acids, Omega-3
2
Ethanol
2
Electrocardiography
2
Educational Status
2
Echocardiography
2
Diet, Mediterranean
2
Blood Specimen Collection
2
Antineoplastic Agents
2
Absorptiometry, Photon
2
zanubrutinib
1
xinmailong
1
sofosbuvir-velpatasvir drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cardiovascular Diseases
×
Liraglutide
×
Clear all
NCT02073929
2019-02-28
LIPT
Herlev Hospital
Phase 4
Completed
72 enrolled
18 charts